{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:48:30Z","timestamp":1788961710936,"version":"build-2803163510"},"reference-count":54,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Thrombocytopenia is a frequent complication in patients with cancer, mostly due to the myelosuppressive effects of antineoplastic therapies. The risk of venous thromboembolism (VTE) in patients with cancer is increased despite low platelet counts. The management of cancer-associated VTE in patients with thrombocytopenia is challenging, as the risk of both recurrent VTE and bleeding complications is high. Moreover, the time-dependent nature of thrombocytopenia over the course of antineoplastic therapies further complicates the management of patients in clinical practice. In the absence of evidence from high-quality studies, the management of anticoagulation therapy for VTE must be personalized, balancing the individual risk of VTE progression and recurrence against the risk of hemorrhage. In the present case-based review, we highlight the clinical challenges that arise upon managing cancer-associated VTE in the setting of present or anticipated thrombocytopenia, summarize the available evidence, and provide a comparative overview of available guidelines.<\/jats:p>","DOI":"10.1182\/hematology.2024000551","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:02:51Z","timestamp":1733497371000},"page":"259-269","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of VTE in the thrombocytopenic cancer patient"],"prefix":"10.1182","volume":"2024","author":[{"given":"Florian","family":"Moik","sequence":"first","affiliation":[{"name":"1 Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria"},{"name":"2 Division of Hematology and Hemostaseology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[{"name":"2 Division of Hematology and Hemostaseology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"4","key":"2024121115403020100_hem2024000551C1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/rth2.12111","article-title":"Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review","volume":"2","author":"Samuelson Bannow","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"2024121115403020100_hem2024000551C2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2023.05.012","article-title":"Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: a systematic review and meta-analysis","volume":"227","author":"Wang","year":"2023","journal-title":"Thromb Res"},{"key":"2024121115403020100_hem2024000551C3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.critrevonc.2018.09.014","article-title":"Antithrombotic medication in cancer-associated thrombocytopenia: current evidence and knowledge gaps","volume":"132","author":"Leader","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"2024121115403020100_hem2024000551C4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.thromres.2020.12.016","article-title":"Challenging anticoagulation cases: cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia\u2014a case-based review of clinical management","volume":"199","author":"Moik","year":"2021","journal-title":"Thromb Res"},{"issue":"9","key":"2024121115403020100_hem2024000551C5","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/s41416-024-02630-w","article-title":"Risk and adverse clinical outcomes of thrombocytopenia among patients with solid tumors-a Danish population-based cohort study","volume":"130","author":"Adelborg","year":"2024","journal-title":"Br J Cancer"},{"key":"2024121115403020100_hem2024000551C6","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1182\/blood-2021-149668","article-title":"Thrombocytopenia among patients with hematologic malignancies and solid tumors: risk and prognosis","volume":"138","author":"Adelborg","year":"2021","journal-title":"Blood"},{"issue":"suppl 2","key":"2024121115403020100_hem2024000551C7","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0049-3848(14)50011-4","article-title":"Thrombocytopenia in cancer patients","volume":"133","author":"Liebman","year":"2014","journal-title":"Thromb Res"},{"issue":"4","key":"2024121115403020100_hem2024000551C8","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"2024121115403020100_hem2024000551C9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-0039-3402429","article-title":"The role of platelets in cancer-related bleeding risk: a systematic review","volume":"46","author":"Larsen","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"2024121115403020100_hem2024000551C10","unstructured":"Zwicker\n              J\n            , LeaderA.\n          Anticoagulation in individuals with thrombocytopenia. UpToDate2024. Accessed 28March2024. https:\/\/www.uptodate.com\/contents\/anticoagulation-in-individuals-with-thrombocytopenia."},{"issue":"S 01","key":"2024121115403020100_hem2024000551C11","article-title":"Incidence and outcomes of bleeding events in patients with cancer: results from a prospective cohort study","volume":"44","author":"Englisch","year":"2024","journal-title":"Hamostaseologie"},{"issue":"14","key":"2024121115403020100_hem2024000551C12","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024121115403020100_hem2024000551C13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"17","key":"2024121115403020100_hem2024000551C14","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1182\/bloodadvances.2022008644","article-title":"The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis","volume":"7","author":"Hsu","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2024121115403020100_hem2024000551C15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"2024121115403020100_hem2024000551C16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jth.15599","article-title":"Extended anticoagulation treatment for cancer-associated thrombosis\u2014rates of recurrence and bleeding beyond 6 months: a systematic review","volume":"20","author":"Moik","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"16","key":"2024121115403020100_hem2024000551C17","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"2024121115403020100_hem2024000551C18","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 International Clinical Practice Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024121115403020100_hem2024000551C19","first-page":"e000610","article-title":"How I treat cancer-associated thrombosis","volume":"5","author":"Moik","year":"2020","journal-title":"ESMO open"},{"issue":"1","key":"2024121115403020100_hem2024000551C20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1055\/s-0039-3402806","article-title":"How I manage cancer-associated thrombosis","volume":"40","author":"Moik","year":"2020","journal-title":"Hamostaseologie"},{"issue":"4","key":"2024121115403020100_hem2024000551C21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/rth2.12359","article-title":"Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"Moik","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"2024121115403020100_hem2024000551C22","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1002\/ajh.24526","article-title":"Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia","volume":"91","author":"Khanal","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"2024121115403020100_hem2024000551C23","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/jth.15748","article-title":"Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: the CAVEaT multicenter prospective cohort","volume":"20","author":"Booth","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"24","key":"2024121115403020100_hem2024000551C24","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1182\/bloodadvances.2021005966","article-title":"Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study","volume":"5","author":"Carney","year":"2021","journal-title":"Blood Adv"},{"key":"2024121115403020100_hem2024000551C25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.thromres.2020.07.021","article-title":"Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia","volume":"195","author":"Lecumberri","year":"2020","journal-title":"Thromb Res"},{"issue":"6","key":"2024121115403020100_hem2024000551C26","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2024121115403020100_hem2024000551C27","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am J Hematol"},{"issue":"7","key":"2024121115403020100_hem2024000551C28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"2024121115403020100_hem2024000551C29","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"2024121115403020100_hem2024000551C30","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024121115403020100_hem2024000551C31","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"issue":"10","key":"2024121115403020100_hem2024000551C32","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"International Initiative on Thrombosis and Cancer (ITAC) Advisory Panel. 2019 International Clinical Practice Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"2024121115403020100_hem2024000551C33","doi-asserted-by":"crossref","first-page":"e12726","DOI":"10.1002\/rth2.12726","article-title":"Management of cancer-associated thrombosis with thrombocytopenia: impact of the ISTH guidance statement","volume":"6","author":"Held","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 1","key":"2024121115403020100_hem2024000551C34","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1182\/blood-2023-191029","article-title":"Risk factors associated with anticoagulant-related bleeding in patients with cancer-associated thrombosis","volume":"142","author":"Loncharich","year":"2023","journal-title":"Blood"},{"key":"2024121115403020100_hem2024000551C35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2023.02.003","article-title":"Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism","volume":"112","author":"Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"suppl 1","key":"2024121115403020100_hem2024000551C36","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood-2023-190887","article-title":"Bleeding and thrombotic outcomes in adults with cancer-associated splanchnic vein thrombosis and thrombocytopenia","volume":"142","author":"Andersen","year":"2023","journal-title":"Blood"},{"issue":"25","key":"2024121115403020100_hem2024000551C37","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood-2014-07-551515","article-title":"How I treat splanchnic vein thrombosis","volume":"124","author":"Ageno","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2024121115403020100_hem2024000551C38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11239-015-1308-1","article-title":"Guidance for the management of venous thrombosis in unusual sites","volume":"41","author":"Ageno","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"2024121115403020100_hem2024000551C39","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jtha.2023.11.017","article-title":"Management of catheter-related upper extremity deep vein thrombosis in patients with cancer: a systematic review and meta-analysis","volume":"22","author":"Wang","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2024121115403020100_hem2024000551C40","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11239-018-1711-5","article-title":"Incidence and outcomes of catheter related thrombosis (CRT) in patients with acute leukemia using a platelet-adjusted low molecular weight heparin regimen","volume":"46","author":"Htun","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2024121115403020100_hem2024000551C41","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S2352-3026(18)30215-1","article-title":"Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study","volume":"6","author":"White","year":"2019","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024121115403020100_hem2024000551C42","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1007\/s00520-021-06598-8","article-title":"Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis","volume":"30","author":"Frere","year":"2022","journal-title":"Support Care Cancer"},{"issue":"5","key":"2024121115403020100_hem2024000551C43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2018-06-820746","article-title":"Treatment of bleeding complications in patients on anticoagulant therapy","volume":"133","author":"Piran","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2024121115403020100_hem2024000551C44","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"2024121115403020100_hem2024000551C45","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1182\/bloodadvances.2019000369","article-title":"Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy","volume":"3","author":"Al-Samkari","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2024121115403020100_hem2024000551C46","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/asheducation-2016.1.620","article-title":"What to do after the bleed: resuming anticoagulation after major bleeding","volume":"2016","author":"Witt","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2024121115403020100_hem2024000551C47","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2007-10-117051","article-title":"The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention","volume":"112","author":"Gerber","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2024121115403020100_hem2024000551C48","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/ajh.26268","article-title":"Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation","volume":"96","author":"Martens","year":"2021","journal-title":"Am J Hematol"},{"key":"2024121115403020100_hem2024000551C49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.thromres.2017.03.012","article-title":"Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: a population-based study","volume":"153","author":"Brunson","year":"2017","journal-title":"Thromb Res"},{"issue":"6","key":"2024121115403020100_hem2024000551C50","first-page":"e40038","article-title":"Inferior vena cava filters and complications: a systematic review","volume":"15","author":"Bajda","year":"2023","journal-title":"Cureus"},{"key":"2024121115403020100_hem2024000551C51","unstructured":"ClinicalTrials.gov. Strategies for anticoagulation in patients with thrombocytopenia and cancer-associated thrombosis (NCT05255003). ClinicalTrials.gov. Accessed 10July2024. https:\/\/clinicaltrials.gov\/study\/NCT05255003."},{"issue":"21","key":"2024121115403020100_hem2024000551C52","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/bloodadvances.2018023895","article-title":"Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study","volume":"2","author":"Gade","year":"2018","journal-title":"Blood Adv"},{"issue":"8","key":"2024121115403020100_hem2024000551C53","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"Hemasphere"},{"issue":"4","key":"2024121115403020100_hem2024000551C54","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/a-1548-4847","article-title":"Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing first-line chemotherapy with FOLFIRINOX or gemcitabine\/nab-paclitaxel","volume":"122","author":"Riedl","year":"2022","journal-title":"Thromb Haemost"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/259\/2346473\/259moik.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/259\/2346473\/259moik.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:06:18Z","timestamp":1733947578000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/259\/526157\/Treatment-of-VTE-in-the-thrombocytopenic-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000551","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}